Literature DB >> 21371605

Fragment screening of infectious disease targets in a structural genomics environment.

Darren W Begley1, Douglas R Davies, Robert C Hartley, Thomas E Edwards, Bart L Staker, Wesley C Van Voorhis, Peter J Myler, Lance J Stewart.   

Abstract

Structural genomics efforts have traditionally focused on generating single protein structures of unique and diverse targets. However, a lone structure for a given target is often insufficient to firmly assign function or to drive drug discovery. As part of the Seattle Structural Genomics Center for Infectious Disease (SSGCID), we seek to expand the focus of structural genomics by elucidating ensembles of structures that examine small molecule-protein interactions for selected infectious disease targets. In this chapter, we discuss two applications for small molecule libraries in structural genomics: unbiased fragment screening, to provide inspiration for lead development, and targeted, knowledge-based screening, to confirm or correct the functional annotation of a given gene product. This shift in emphasis results in a structural genomics effort that is more engaged with the infectious disease research community, and one that produces structures of greater utility to researchers interested in both protein function and inhibitor development. We also describe specific methods for conducting high-throughput fragment screening in a structural genomics context by X-ray crystallography.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21371605      PMCID: PMC4472360          DOI: 10.1016/B978-0-12-381274-2.00021-2

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  101 in total

Review 1.  Clinical practice. Latent tuberculosis infection.

Authors:  Robert M Jasmer; Payam Nahid; Philip C Hopewell
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

2.  A 'rule of three' for fragment-based lead discovery?

Authors:  Miles Congreve; Robin Carr; Chris Murray; Harren Jhoti
Journal:  Drug Discov Today       Date:  2003-10-01       Impact factor: 7.851

Review 3.  Predicting protein druggability.

Authors:  Philip J Hajduk; Jeffrey R Huth; Christin Tse
Journal:  Drug Discov Today       Date:  2005-12       Impact factor: 7.851

4.  Free-solution, label-free molecular interactions studied by back-scattering interferometry.

Authors:  Darryl J Bornhop; Joey C Latham; Amanda Kussrow; Dmitry A Markov; Richard D Jones; Henrik S Sørensen
Journal:  Science       Date:  2007-09-21       Impact factor: 47.728

5.  On sampling of fragment space.

Authors:  Gergely M Makara
Journal:  J Med Chem       Date:  2007-06-14       Impact factor: 7.446

6.  Isoprenoid biosynthesis: the evolution of two ancient and distinct pathways across genomes.

Authors:  B M Lange; T Rujan; W Martin; R Croteau
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

7.  Biosynthesis of terpenoids. 2C-Methyl-D-erythritol 2,4-cyclodiphosphate synthase (IspF) from Plasmodium falciparum.

Authors:  F Rohdich; W Eisenreich; J Wungsintaweekul; S Hecht; C A Schuhr; A Bacher
Journal:  Eur J Biochem       Date:  2001-06

8.  Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography.

Authors:  Douglas R Davies; Bjorn Mamat; Olafur T Magnusson; Jeff Christensen; Magnus H Haraldsson; Rama Mishra; Brian Pease; Erik Hansen; Jasbir Singh; David Zembower; Hidong Kim; Alex S Kiselyov; Alex B Burgin; Mark E Gurney; Lance J Stewart
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

9.  One scaffold, three binding modes: novel and selective pteridine reductase 1 inhibitors derived from fragment hits discovered by virtual screening.

Authors:  Chidochangu P Mpamhanga; Daniel Spinks; Lindsay B Tulloch; Emma J Shanks; David A Robinson; Iain T Collie; Alan H Fairlamb; Paul G Wyatt; Julie A Frearson; William N Hunter; Ian H Gilbert; Ruth Brenk
Journal:  J Med Chem       Date:  2009-07-23       Impact factor: 7.446

10.  Dxr is essential in Mycobacterium tuberculosis and fosmidomycin resistance is due to a lack of uptake.

Authors:  Amanda C Brown; Tanya Parish
Journal:  BMC Microbiol       Date:  2008-05-20       Impact factor: 3.605

View more
  4 in total

Review 1.  Recent contributions of structure-based drug design to the development of antibacterial compounds.

Authors:  Bart L Staker; Garry W Buchko; Peter J Myler
Journal:  Curr Opin Microbiol       Date:  2015-10       Impact factor: 7.934

2.  Probing conformational states of glutaryl-CoA dehydrogenase by fragment screening.

Authors:  Darren W Begley; Douglas R Davies; Robert C Hartley; Stephen N Hewitt; Amanda L Rychel; Peter J Myler; Wesley C Van Voorhis; Bart L Staker; Lance J Stewart
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2011-08-13

3.  Structural genomics of infectious disease drug targets: the SSGCID.

Authors:  Robin Stacy; Darren W Begley; Isabelle Phan; Bart L Staker; Wesley C Van Voorhis; Gabriele Varani; Garry W Buchko; Lance J Stewart; Peter J Myler
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2011-08-13

4.  Naegleria fowleri: Protein structures to facilitate drug discovery for the deadly, pathogenic free-living amoeba.

Authors:  Logan Tillery; Kayleigh Barrett; Jenna Goldstein; Jared W Lassner; Bram Osterhout; Nathan L Tran; Lily Xu; Ryan M Young; Justin Craig; Ian Chun; David M Dranow; Jan Abendroth; Silvia L Delker; Douglas R Davies; Stephen J Mayclin; Brandy Calhoun; Madison J Bolejack; Bart Staker; Sandhya Subramanian; Isabelle Phan; Donald D Lorimer; Peter J Myler; Thomas E Edwards; Dennis E Kyle; Christopher A Rice; James C Morris; James W Leahy; Roman Manetsch; Lynn K Barrett; Craig L Smith; Wesley C Van Voorhis
Journal:  PLoS One       Date:  2021-03-24       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.